Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysis
Open Access
- 3 August 2010
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 62 (8), 1166-1173
- https://doi.org/10.1002/acr.20176
Abstract
Objective Disease relapses are common for patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). The role of low‐dose glucocorticoids (GC) in relapse prevention is controversial. We undertook a systematic review and meta‐analysis to determine if GC target doses influence relapses of AAV. Methods Medline, EMBase, and Cochrane databases were searched for observational studies and randomized controlled trials of treatment of AAV that included a predefined GC treatment plan. The association of GC target dose with the proportion of relapses in studies was assessed using meta‐regression and multilevel generalized linear modeling. Results Thirteen studies (983 patients) were identified for inclusion. There were no studies directly comparing GC regimens. We classified 288 patients as having a nonzero GC target dose by study end and 695 patients as having a zero GC target dose by study end. The pooled proportion of patients with a relapse was 36% (95% confidence interval [95% CI] 25–47%). GC regimen was the most significant variable explaining the variability between the proportions of patients with relapses. The proportion of patients with a relapse was 14% (95% CI 10–19%) in nonzero GC target dose studies and 43% (95% CI 33–52%) in zero GC target dose studies. Differences other than GC regimens exist between studies that complicate the comparability of trials and isolation of the variability in relapses due to GC target alone. Conclusion Studies with longer courses of GC in AAV are associated with fewer relapses. These results have implications for study design and outcome assessment in clinical trials of AAV.Keywords
This publication has 36 references indexed in Scilit:
- Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosisRheumatology, 2007
- Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamideAnnals Of The Rheumatic Diseases, 2007
- Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Arthritis & Rheumatism, 2005
- Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty‐five patientsArthritis Care & Research, 2003
- High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low‐dose methotrexateArthritis Care & Research, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- An analysis of forty‐two wegener's granulomatosis patients treated with methotrexate and prednisoneArthritis & Rheumatism, 1995
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Treatment of Polyarteritis Nodosa with Cortisone: Results After Three Years: Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity PanelBMJ, 1960